Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma.

Understanding the profile of oncogene and tumor suppressor gene mutations with their interactions and impact on the prognosis of multiple myeloma (MM) can improve the definition of disease subsets and identify pathways important in disease pathobiology. Using integrated genomics of 1273 newly diagnosed patients with MM, we identified 63 driver genes, some of which are novel, including IDH1, IDH2, HUWE1, KLHL6, and PTPN11 Oncogene mutations are significantly more clonal than tumor suppressor mutations, indicating they may exert a bigger selective pressure. Patients with more driver gene abnormalities are associated with worse outcomes, as are identified mechanisms of genomic instability. Oncogenic dependencies were identified between mutations in driver genes, common regions of copy number change, and primary translocation and hyperdiploidy events. These dependencies included associations with t(4;14) and mutations in FGFR3, DIS3, and PRKD2; t(11;14) with mutations in CCND1 and IRF4; t(14;16) with mutations in MAF, BRAF, DIS3, and ATM; and hyperdiploidy with gain 11q, mutations in FAM46C, and MYC rearrangements. These associations indicate that the genomic landscape of myeloma is predetermined by the primary events upon which further dependencies are built, giving rise to a nonrandom accumulation of genetic hits. Understanding these dependencies may elucidate potential evolutionary patterns and lead to better treatment regimens.

[1]  Pingping Qu,et al.  A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis , 2018, Leukemia.

[2]  Chuang Tan,et al.  Universal Patterns of Selection in Cancer and Somatic Tissues , 2018, Cell.

[3]  James X. Sun,et al.  Loss of heterozygosity as a marker of homologous repair deficiency in multiple myeloma: a role for PARP inhibition? , 2018, Leukemia.

[4]  D. Nowis,et al.  The non-canonical poly(A) polymerase FAM46C acts as an onco-suppressor in multiple myeloma , 2017, Nature Communications.

[5]  N. Schultz,et al.  Conditional Selection of Genomic Alterations Dictates Cancer Evolution and Oncogenic Dependencies. , 2017, Cancer cell.

[6]  I. Flinn,et al.  Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. , 2017, Blood.

[7]  Caleb K. Stein,et al.  The varied distribution and impact of RAS codon and other key DNA alterations across the translocation cyclin D subgroups in multiple myeloma , 2017, Oncotarget.

[8]  J. Qiu,et al.  IDH1 R132H Mutation Enhances Cell Migration by Activating AKT-mTOR Signaling Pathway, but Sensitizes Cells to 5-FU Treatment as NADPH and GSH Are Reduced , 2017, PloS one.

[9]  Gabriela Alexe,et al.  Characterizing genomic alterations in cancer by complementary functional associations , 2016, Nature Biotechnology.

[10]  R. S. Shmookler Reis,et al.  A Cyclin-Dependent Kinase Inhibitor, Dinaciclib, Impairs Homologous Recombination and Sensitizes Multiple Myeloma Cells to PARP Inhibition , 2015, Molecular Cancer Therapeutics.

[11]  K. Dutton-Regester,et al.  Recurrent inactivating RASA2 mutations in melanoma , 2015, Nature Genetics.

[12]  A. Labno,et al.  DIS3 shapes the RNA polymerase II transcriptome in humans by degrading a variety of unwanted transcripts , 2015, Genome research.

[13]  Gordon Cook,et al.  Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Kathleen Marchal,et al.  SomInaClust: detection of cancer genes based on somatic mutation patterns of inactivation and clustering , 2015, BMC Bioinformatics.

[15]  Gordon Cook,et al.  APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma , 2014, Nature Communications.

[16]  J. Cleveland,et al.  Tipping the MYC–MIZ1 balance: targeting the HUWE1 ubiquitin ligase selectively blocks MYC-activated genes , 2014, EMBO molecular medicine.

[17]  B. Leggett,et al.  Isocitrate dehydrogenase 1 R132C mutation occurs exclusively in microsatellite stable colorectal cancers with the CpG island methylator phenotype , 2014, Epigenetics.

[18]  N. Potter,et al.  Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma , 2014, Leukemia.

[19]  Chris Sander,et al.  Frequent disruption of the RB pathway in indolent follicular lymphoma suggests a new combination therapy , 2014, The Journal of experimental medicine.

[20]  C. Rudin,et al.  MYC, MAX, and small cell lung cancer. , 2014, Cancer discovery.

[21]  G. Morgan,et al.  Translocations at 8q24 juxtapose MYC with genes that harbor superenhancers resulting in overexpression and poor prognosis in myeloma patients , 2014, Blood Cancer Journal.

[22]  J. Keats,et al.  Promiscuous Rearrangements of the MYC Locus Hijack Enhancers and Super-Enhancers to Dysregulate MYC Expression in Multiple Myeloma , 2014, Leukemia.

[23]  G. Parmigiani,et al.  Heterogeneity of genomic evolution and mutational profiles in multiple myeloma , 2014, Nature Communications.

[24]  A. McKenna,et al.  Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. , 2014, Cancer cell.

[25]  Chris Sander,et al.  Emerging landscape of oncogenic signatures across human cancers , 2013, Nature Genetics.

[26]  Lisa J. Murray,et al.  Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms , 2013, Leukemia.

[27]  M. Shen Chromoplexy: a new category of complex rearrangements in the cancer genome. , 2013, Cancer cell.

[28]  Richard A. Moore,et al.  The E3 ubiquitin ligase UBR5 is recurrently mutated in mantle cell lymphoma. , 2013, Blood.

[29]  K. Kinzler,et al.  Cancer Genome Landscapes , 2013, Science.

[30]  D. Schadendorf,et al.  A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. , 2013, Cancer discovery.

[31]  A. Ashworth,et al.  Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma. , 2012, Blood.

[32]  G. Morgan,et al.  The genetic architecture of multiple myeloma , 2012, Nature Reviews Cancer.

[33]  M. Stratton,et al.  Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. , 2011, The New England journal of medicine.

[34]  N. Munshi,et al.  Chromothripsis identifies a rare and aggressive entity among newly diagnosed multiple myeloma patients. , 2011, Blood.

[35]  A. Hauschild,et al.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.

[36]  Trevor J Pugh,et al.  Initial genome sequencing and analysis of multiple myeloma , 2011, Nature.

[37]  David N. Boone,et al.  Egr1 mediates p53-independent c-Myc–induced apoptosis via a noncanonical ARF-dependent transcriptional mechanism , 2010, Proceedings of the National Academy of Sciences.

[38]  S. Lonial,et al.  Bortezomib-induced "BRCAness" sensitizes multiple myeloma cells to PARP inhibitors. , 2010, Blood.

[39]  G. Morgan,et al.  A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value. , 2010, Blood.

[40]  J. Reis-Filho,et al.  Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF , 2010, Cell.

[41]  L. Staudt,et al.  IRF4 addiction in multiple myeloma , 2008, Nature.

[42]  L. Bruhn,et al.  Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. , 2007, Cancer cell.

[43]  A. Baldwin,et al.  Nuclear factor-κB and inhibitor of κB kinase pathways in oncogenic initiation and progression , 2006, Oncogene.

[44]  J. Keats,et al.  Ten years and counting: so what do we know about t(4;14)(p16;q32) multiple myeloma , 2006, Leukemia & lymphoma.

[45]  Bart Barlogie,et al.  Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. , 2005, Blood.

[46]  Mathew J Garnett,et al.  Guilty as charged: B-RAF is a human oncogene. , 2004, Cancer cell.

[47]  D. Barford,et al.  Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF , 2004, Cell.

[48]  M. Loh,et al.  Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis. , 2004, Blood.

[49]  K. Kinzler,et al.  Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status , 2002, Nature.

[50]  Michael A. Patton,et al.  Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome , 2001, Nature Genetics.

[51]  J. Dudley,et al.  Integrative network analysis identifies novel drivers of pathogenesis and progression in newly diagnosed multiple myeloma , 2018, Leukemia.

[52]  Trevor J Pugh,et al.  Mutational heterogeneity in cancer and the search for new cancer genes , 2014 .